+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Postbiotic Supplements - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 70 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292600
The global postbiotic supplements market size is valued at USD 1.8 billion in 2026 and is projected to reach USD 2.9 billion by 2032, registering a CAGR of 8.83% during the forecast period (2027-2032). This report is Segmented by Product Type (Capsules and Tablets, Powders, and More), Target Health Benefit (Digestive Health, Immune Support, and More), Distribution Channel (Hypermarkets and Supermarkets, Pharmacies and More), and Geography (North America, Europe, Asia-Pacific, and More). Market Forecasts are Provided in Terms of Value (USD) and Volume (Tons).

Global Postbiotic Supplements Market Trends and Insights

Rising Awareness of Gut Health and Digestive Wellness

Growing consumer awareness of gut health and digestive wellness creates opportunities for postbiotics, which are preparations of inanimate microorganisms and/or their components that confer a health benefit on the host. Their potential use in digestive health supplements and functional nutrition products allows manufacturers to target consumers seeking support for gastrointestinal wellness. As digestive health remains a key category within the postbiotics market, companies can differentiate their offerings through clearly defined product benefits, evidence-based formulations, and transparent labelling. This creates opportunities to position postbiotics as an additional option within the broader digestive wellness market.

Growing Demand for Immune-Support Supplements

Growing interest in immune health creates opportunities for postbiotics as ingredients in dietary supplements and functional nutrition products. Postbiotic preparations are being investigated for their potential effects on host immune responses, although benefits depend on the specific microbial preparation and supporting evidence. The International Scientific Association for Probiotics and Prebiotics (ISAPP) emphasizes that a product must demonstrate a health benefit to qualify as a postbiotic under its consensus definition. Manufacturers can respond to this demand by developing targeted formulations supported by strain-specific research, appropriate safety assessments, and substantiated health claims. This creates opportunities to differentiate immune-support products while maintaining scientific credibility and avoiding unsupported generalizations about efficacy.

Limited Consumer Awareness of Postbiotics

Limited familiarity with postbiotics and their distinction from probiotics and prebiotics may constrain consumer understanding and product adoption. Unlike more established supplement categories, postbiotics require consumers to understand that they contain inanimate microorganisms or their components and that benefits depend on the specific preparation. The U.S. National Institutes of Health's Office of Dietary Supplements provides consumer guidance on probiotics, including their potential benefits and limitations, illustrating the importance of accessible information when consumers evaluate microbial supplements. Manufacturers may need to invest in consumer education, transparent ingredient descriptions, and clear explanations of product benefits to improve category understanding. Without effective communication and credible evidence, consumers may find it difficult to distinguish postbiotic products from established alternatives.

Other drivers and restraints analyzed in the report include:
  • Preference for Shelf-Stable Alternatives to Live Probiotics
  • Expansion of Preventive Healthcare and Functional Nutrition
  • Regulatory and Labeling Challenges

Segment Analysis

Capsules and tablets accounted for 42.00% of the global postbiotics market in 2026, making them the largest product-type segment. Their leading position reflects the established use of these formats in dietary supplements, where standardized serving sizes, portability, and convenient consumption support their suitability for daily wellness routines. These formats also allow manufacturers to incorporate postbiotic ingredients into products targeting digestive health, immune support, and general wellness.

Powder supplements are projected to be the fastest-growing product-type segment, with a CAGR of 10.50% from 2027 to 2032. Their growth potential is supported by their flexibility for incorporation into beverages, shakes, and other nutritional preparations, as well as the ability to adjust serving sizes and combine postbiotic ingredients with other functional components. For the postbiotics market assessment, the distinction between capsules and tablets and powder supplements is important because each format offers different consumption options and formulation possibilities.

Complete Report Scope:

  • By Product Type
    • Capsules and Tablets
    • Powders
    • Liquids
    • Other Formats
  • By Target Health Benefit
    • Digestive Health
    • Immune Support
    • General Wellness and Other Benefits
    • Others
  • By Distribution channel
    • Hypermarkets and Supermarkets
      • Pharmacies & Health Stores
      • Online Retail
      • Other off-trade channels
  • By Geography
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Thailand
      • Australia
      • Rest of Asia-Pacific
    • South America
      • Brazil
      • Colombia
      • Rest of South America
    • Middle East and Africa
      • South Africa
      • Saudi Arabia
      • United Arab Emirates
      • Rest of Middle East and Africa

Geography Analysis

North America was the largest regional market for postbiotics in 2026, accounting for 36.00% of the global market. The region's established dietary supplement industry and availability of products targeting digestive health, immune support, and general wellness provide a foundation for postbiotic product development. Manufacturers can differentiate their portfolios through evidence-based formulations, clearly communicated product benefits, and convenient formats distributed through pharmacies, health stores, and online retail channels. The verified 2025 regional market share has not been provided, so the 2026 figure is used for the regional comparison.

Asia-Pacific is projected to be the fastest-growing regional market, with a CAGR of 9.50% from 2027 to 2032. Opportunities may arise from the expansion of functional nutrition and dietary supplement categories, alongside the potential to increase postbiotic product availability through pharmacies, specialty health retailers, and e-commerce platforms. China, Japan, India, Thailand, Australia, and other markets within the region differ in consumer preferences, retail infrastructure, and regulatory requirements, creating varied opportunities for manufacturers. Market expansion will depend on consumer awareness, product affordability, suitable formulations, effective distribution, and compliance with local food and supplement regulations.

Across the global market, regional strategies need to reflect differences in consumer awareness, supplement purchasing behaviour, distribution infrastructure, and regulatory requirements. North America offers the largest established market, while Asia-Pacific presents the strongest forecast growth opportunity among the supplied regional comparisons. Europe, including the United Kingdom, Germany, France, Italy, Spain, and other markets, also provides opportunities for product development and distribution expansion. South America, including Brazil, Colombia, and other markets, may offer opportunities as postbiotic supplements become more accessible. In the Middle East and Africa, including South Africa, Saudi Arabia, the United Arab Emirates, and other markets, market development will depend on product availability, consumer awareness, and local regulatory conditions.


List of Companies Covered in this Report:

  • DSM-Firmenich AG
  • Cargill, Incorporated
  • Archer-Daniels-Midland Company (ADM)
  • Kerry Group plc
  • Sabinsa Corporation
  • Kirin Holdings Company, Limited
  • SCD Probiotics
  • Biofarma Group
  • Probi AB
  • Culturelle (i-Health, Inc.)
  • VSL Pharmaceuticals
  • Ritual
  • Metagenics, Inc.
  • Lallemand Inc.
  • ABbiotek Health
  • Sirio Pharma Co., Ltd.
  • Postbiotica S.r.l.
  • Lesaffre Group
  • Glac Biotech Co., Ltd.
  • Postbiotics Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Awareness of Gut Health and Digestive Wellness
4.2.2 Growing Demand for Immune-Support Supplements
4.2.3 Preference for Shelf-Stable Alternatives to Live Probiotics
4.2.4 Expansion of Preventive Healthcare and Functional Nutrition
4.2.5 Innovation in Postbiotic Supplement Formulations
4.2.6 Expanding online and modern retail distribution
4.3 Market Restraints
4.3.1 Limited Consumer Awareness of Postbiotics
4.3.2 Regulatory and Labeling Challenges
4.3.3 Limited Clinical Evidence for Certain Health Claims
4.3.4 Competition from Probiotic and Prebiotic Supplements
4.4 Consumer Behaviour Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE AND VOLUME)
5.1 By Product Type
5.1.1 Capsules and Tablets
5.1.2 Powders
5.1.3 Liquids
5.1.4 Other Formats
5.2 By Target Health Benefit
5.2.1 Digestive Health
5.2.2 Immune Support
5.2.3 General Wellness and Other Benefits
5.2.4 Others
5.3 By Distribution channel
5.3.1 Hypermarkets and Supermarkets
5.3.1.1 Pharmacies & Health Stores
5.3.1.2 Online Retail
5.3.1.3 Other off-trade channels
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.2 Europe
5.4.2.1 United Kingdom
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Thailand
5.4.3.5 Australia
5.4.3.6 Rest of Asia-Pacific
5.4.4 South America
5.4.4.1 Brazil
5.4.4.2 Colombia
5.4.4.3 Rest of South America
5.4.5 Middle East and Africa
5.4.5.1 South Africa
5.4.5.2 Saudi Arabia
5.4.5.3 United Arab Emirates
5.4.5.4 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Positioning Analysis
6.4 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Products and Services, and analysis of Recent Developments)
6.4.1 DSM-Firmenich AG
6.4.2 Cargill, Incorporated
6.4.3 Archer-Daniels-Midland Company (ADM)
6.4.4 Kerry Group plc
6.4.5 Sabinsa Corporation
6.4.6 Kirin Holdings Company, Limited
6.4.7 SCD Probiotics
6.4.8 Biofarma Group
6.4.9 Probi AB
6.4.10 Culturelle (i-Health, Inc.)
6.4.11 VSL Pharmaceuticals
6.4.12 Ritual
6.4.13 Metagenics, Inc.
6.4.14 Lallemand Inc.
6.4.15 ABbiotek Health
6.4.16 Sirio Pharma Co., Ltd.
6.4.17 Postbiotica S.r.l.
6.4.18 Lesaffre Group
6.4.19 Glac Biotech Co., Ltd.
6.4.20 Postbiotics Inc.
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • DSM-Firmenich AG
  • Cargill, Incorporated
  • Archer-Daniels-Midland Company (ADM)
  • Kerry Group plc
  • Sabinsa Corporation
  • Kirin Holdings Company, Limited
  • SCD Probiotics
  • Biofarma Group
  • Probi AB
  • Culturelle (i-Health, Inc.)
  • VSL Pharmaceuticals
  • Ritual
  • Metagenics, Inc.
  • Lallemand Inc.
  • ABbiotek Health
  • Sirio Pharma Co., Ltd.
  • Postbiotica S.r.l.
  • Lesaffre Group
  • Glac Biotech Co., Ltd.
  • Postbiotics Inc.